01:40:27 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-21 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-07-02 Extra Bolagsstämma 2024
2024-05-23 Kvartalsrapport 2024-Q1
2024-03-22 X-dag ordinarie utdelning CURAS 0.00 DKK
2024-03-21 Årsstämma 2024
2024-02-22 Bokslutskommuniké 2023
2023-11-23 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-25 Kvartalsrapport 2023-Q1
2023-03-31 X-dag ordinarie utdelning CURAS 0.00 DKK
2023-03-30 Årsstämma 2023
2023-02-23 Bokslutskommuniké 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-24 Kvartalsrapport 2022-Q1
2022-04-27 Årsstämma 2022
2022-03-25 X-dag ordinarie utdelning CURAS 0.00 DKK
2022-02-24 Bokslutskommuniké 2021
2021-11-25 Kvartalsrapport 2021-Q3
2021-08-24 Kvartalsrapport 2021-Q2
2021-06-01 Extra Bolagsstämma 2021
2021-05-20 Kvartalsrapport 2021-Q1
2021-03-26 X-dag ordinarie utdelning CURAS 0.00 DKK
2021-03-25 Årsstämma 2021
2021-02-24 Bokslutskommuniké 2020
2020-11-30 Kvartalsrapport 2020-Q3

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriMedicinteknik
Curasight är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom utveckling av teknologiska produkter. Produktportföljen är bred och har sin huvudsakliga fokus på utveckling av produkter inom området Positron Emissions Tomography (PET). Verksamheten drivs med störst närvaro inom Skandinavien. Curasight har sitt huvudkontor i Köpenhamn.
2024-05-23 07:00:00
Business Highlights during the first quarter 2024
  • Announcing the achievement of the first milestone under the agreement with Curium Inc. to develop uTRACE[®] for improving diagnosis of prostate cancer.
  • The Company remains committed to accelerating its therapeutic strategy and is currently evaluating alternative financing options.
  • After the end of Q1 the Company received acceptance of the clinical trial application from the European Medicines Agency for the investigation of uTRACE[®] in a phase 2 trial.

Copenhagen, Denmark, 23 May 2024 - Curasight A/S ("Curasight" or "the Company" - TICKER: CURAS) hereby publishes the Interim report Q1 2024. The interim report is available as an attached file to this release and on the Company's website. Below is a summary of the report.

"We had another busy quarter as we have continued to build on our successes from the past year. In particularly we were pleased to receive the first milestone payment from Curium under our agreement for uTRACE[®] in prostate cancer. This shows the progress in the uTRACE[®] product as the milestone relates to validation of GMP manufacturing of the finished product.", stated Curasight's CEO Ulrich Krasilnikoff. We also updated our clinical strategy to accelerate development of our therapeutic platform uTREAT[®] and ensure parallel development with our uTRACE[®] diagnosis platform. Finally, due to the challenging climate at the capital market we decided to withdraw a planned right issue in Q1 with the purpose to pursue other options. We look forward to being able to announce progress in these alternative funding options soon."

Q1 (2024-01-01 - 2024-03-31)
  • Gross loss amounted to kDKK -7,385 (kDKK -4,656)
  • Operating loss amounted to kDKK -9,376 (kDKK -6,184)
  • Loss before tax amounted to kDKK -9,367 (kDKK -6,186)
  • Loss for the period amounted to kDKK -7,992 (kDKK -4,826)
  • Total assets amounted to kDKK 27,574 (kDKK 54,745)
  • Equity ratio amounted to 84,8% (96,3%)
  • Earnings per share amounted to DKK -0,40 (DKK -0,24)